Мodernization of the Strategic Priorities of the Pharmaceutical Industry in the Conditions of Sanctions Limitations in the RUSSIAN Economy
Тhis article discusses the targets and interim results of the implementation of the «Pharma 2020» Strategy. The Strategy is a symbiosis of import substitution and modernization trends in the Russian government. The analysis of the impact of economic shocks in 2014 leads to the conclusion on the impossibility of the continuation of the previous model of growth of the Russian pharmaceutical industry. The strategic priorities of its development should be turned in the direction of import substitution subsidy and the restriction of competition in the production of medicines.